When used to analyze EREG and AREG in RAS WT CRC patients receiving cetuximab or panitumumab therapy, the dichotomized model could predict significant effects on survival across primary tumor location, chemotherapy regimens, and EGFR-targeted mAbs [64]. Here, EREG is linked to colorectal carcinoma.